Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00035568 · ClinicalTrials.gov registry record · Phase 4

A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes

A Phase 4 study, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 4
Development phase

NCT00035568: Completed Phase 4 study, sponsored by Bristol-Myers Squibb.

NCT00035568 is a Phase 4 study that has completed, run by Bristol-Myers Squibb. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00035568, a Phase 4 study, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 4
Development phase

Study Summary

The purpose of this clinical research study is to support earlier observations that Glucovance controls glucose levels after a mean, and improves overall glucose control better than metformin or glyburide therapy alone in adults with type 2 diabetes.

Interventions

  • DRUG Glucovance (metformin HCl/glyburide)
  • DRUG or Metformin HCl alone
  • DRUG or Glyburide alone.

Trial Details

FieldValue
Start Date 2002-02
Est. Completion 2003-06
Phase Phase 4
Bristol-Myers Squibb

1,025 total trials

What the finished NCT00035568 record still lists

NCT00035568 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 3 interventions - of which Glucovance (metformin HCl/glyburide) is the first listed.

NCT00035568 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00035568 about?

NCT00035568 is a clinical study titled "A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes". The purpose of this clinical research study is to support earlier observations that Glucovance controls glucose levels after a mean, and improves overall glucose control better than metformin or glyburide therapy alone in adults with type 2 diabetes.

What is the current status of trial NCT00035568?

This trial is currently completed. It is a Phase 4 study. The study started on 2002-02. Estimated completion is 2003-06.

What interventions are being tested in trial NCT00035568?

The interventions under investigation include: Glucovance (metformin HCl/glyburide) (DRUG), or Metformin HCl alone (DRUG), or Glyburide alone. (DRUG).

Who is sponsoring clinical trial NCT00035568?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00035568, the US trial registry maintained by the National Library of Medicine. NCT00035568 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.